This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I
wherein X
1
, X
2
, X
3
, R
2
, R
3
, R
4
, R
5
, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
Compounds of the formula I
in which R
1
, X and Y have the meanings indicated in Claim
1,
are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity
申请人:Merck Patent GmbH
公开号:US09120805B2
公开(公告)日:2015-09-01
Compounds of the formula I
in which R1, X and Y have the meanings indicated in Claim 1,
are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I:
wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
本公开涉及作为 Syk 抑制剂的化合物及其在治疗各种疾病(包括癌症和炎症)中的用途。在特定的实施方案中,化合物的结构如式 I 所示:
其中 X1、X2、X3、R2、R3、R4、R5 和 Y 如本文所述。本公开进一步提供了包括式 I 的化合物或其药学上可接受的盐的药物组合物,以及使用这些化合物和组合物治疗由 Syk 介导的病症的方法。